Chindex Medical and Medvio have entered into a collaboration agreement with an advanced imaging and radiation therapy technologies provider iCAD.
Under the agreement, Chindex will distribute iCAD's Xoft Axxent Electronic Brachytherapy system in China, while Medvio in Russia.
iCAD said the first breast cancer patient was treated with intraoperative radiation therapy (IORT) using its isotope-free Xoft radiation therapy system in Taiwan.
iCAD president and CEO Ken Ferry said the company is seeing growing interest in IORT among surgeons and radiation oncologists who want to offer patients advanced radiation therapy treatment options.
"We expect increased international demand will strengthen our global commercial strategy," Ferry added.
Using a proprietary miniaturized x-ray as the radiation source, the FDA-cleared and CE-marked device delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs.
Chindex Medical chief operating officer Elyse Beth Silverberg said breast cancer is predicted to be the most common cancer in Chinese women over the next 20 years.
"The availability of the Xoft System in China, including Hong Kong and Macau, will provide our customers access to the most advanced cancer treatments, including Intraoperative Radiation Therapy for early stage breast cancer," Silverberg added.
Medvio principal Lori Woods said, "With the Xoft System, physicians will be able to use advanced technology to treat many more patients with breast, endometrial and cervical cancer."
A post-market study is also underway to assess the safety and efficacy of IORT with the radiation therapy device.
Medvio principal Lori Woods said, "With the Xoft System, physicians will be able to use advanced technology to treat many more patients with breast, endometrial and cervical cancer."
